Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Abstract
BACKGROUND: This study was undertaken to determine whether use of the direct renin inhibitor aliskiren would reduce cardiovascular and renal events in patients with type 2 diabetes and chronic kidney disease, cardiovascular disease, or both. METHODS: In a double-blind fashion, we randomly assigned 8561 patients to aliskiren (300 mg daily) or placebo as an adjunct to an angiotensin-converting-enzyme inhibitor or an angiotensin-receptor blocker. The primary end point was a composite of the time to cardiovascular death or a first occurrence of cardiac arrest with resuscitation; nonfatal myocardial infarction; nonfatal stroke; unplanned hospitalization for heart failure; end-stage renal disease, death attributable to kidney failure, or the need for renal-replacement therapy with no dialysis or transplantation available or initiated; or doubling of the baseline serum creatinine level. RESULTS: The trial was stopped prematurely after the second interim efficacy analysis. After a median follow-up of 32.9 months, the primary end point had occurred in 783 patients (18.3%) assigned to aliskiren as compared with 732 (17.1%) assigned to placebo (hazard ratio, 1.08; 95% confidence interval [CI], 0.98 to 1.20; P=0.12). Effects on secondary renal end points were similar. Systolic and diastolic blood pressures were lower with aliskiren (between-group differences, 1.3 and 0.6 mm Hg, respectively) and the mean reduction in the urinary albumin-to-creatinine ratio was greater (between-group difference, 14 percentage points; 95% CI, 11 to 17). The proportion of patients with hyperkalemia (serum potassium level, ≥6 mmol per liter) was significantly higher in the aliskiren group than in the placebo group (11.2% vs. 7.2%), as was the proportion with reported hypotension (12.1% vs. 8.3%) (P<0.001 for both comparisons). CONCLUSIONS: The addition of aliskiren to standard therapy with renin-angiotensin system blockade in patients with type 2 diabetes who are at high risk for cardiovascular and renal events is not supported by these data and may even be harmful. (Funded by Novartis; ALTITUDE ClinicalTrials.gov number, NCT00549757.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ACE inhibitors and ARBs should not be used together and should be used with caution with spironolactone to avoid hyperkalemia or AKI.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [259]
In the citing paper
“However, combination therapy was associated with a higher rate of hyperkalemia and AKI, 85,86”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Long-term outcome trials in patients with diabetes and CKD demonstrated no kidney or cardiovascular bene fi t of RAS blockade with combined therapy to block the RAS versus the single use of RAS inhibitors.”
From KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease (2022) · cites this paper as [86]
In the citing paper
“Prior trials of dual renin–angiotensin system blockade have failed to show cardiovascular or kidney protection among patients with CKD and type 2 diabetes”
From Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis (2022) · cites this paper as [25]
In the citing paper
“markedly lower than in trials of dual RAS blockade (4.8% with combination therapy with a direct renin inhibitor and an ACE inhibitor or ARB 20 and 9.2% with dual ACE inhibitor and ARB therapy 22 )”
From Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes (2020) · cites this paper as [20]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationHaffner, S. M., Lehto, S., Rönnemaa, T., Pyörälä, K., & Laakso, M. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807233390404 · Cited by 7,000
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes
Gæde, P., Vedel, P., Larsen, N., Jensen, G. V. H., Parving, H.-H., & Pedersen, O. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021778 · Cited by 4,378
Self-citationTelmisartan, ramipril, or both in patients at high risk for vascular events
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0801317 · Cited by 3,502
A Randomized Trial of the Angiotensin-Receptor Blocker Valsartan in Chronic Heart Failure
Cohn, J. N., & Tognoni, G. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010713 · Cited by 3,108
The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes
Parving, H.-H., Lehnert, H., Bröchner-Mortensen, J., Gomis, R., Andersen, S., & Arner, P. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011489 · Cited by 2,873
Self-citation
Research works printed but not linked: 1
- Pfeffer MA, 2010, Dial Cardiovasc Med, 15, 130
Cited by
Items 801–900 of 1,000
Jaimes, E. A., & Hovater (2013) · Integrated Blood Pressure Control · doi:10.2147/ibpc.s32649 · Cited by 6
“61 The ALiskiren Trial In Type 2 diabetes Using cardio-renal Disease Endpoints (ALTITUDE) trial 62 evaluated the addition of high-dose aliskiren (300 mg) or placebo to ongoing ACE inhibitor or ARB therapy in patients with type 2 diabetes and chronic kidney disease or cardiovascular disease.”
MethodA Paradigm Shift for the Concept of Diabetic Nephropathy
Gohda, T., & Tomino, Y. (2014) · Juntendō Igaku/Juntendo igaku · doi:10.14789/jmj.60.293 · Cited by 6
Stanton, R. C. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0391-y · Cited by 6
Soji, K., Doi, S., Nakashima, A., Sasaki, K., Kawai, T., Aoki, A., Kyuden, Y., Fujiwara, K., Yokoyama, Y., & Masaki, T. (2014) · Clinical and Experimental Nephrology · doi:10.1007/s10157-014-1044-4 · Cited by 6
“As a result of the interim analysis of the ALTITUDE study [12, 13], our study was discontinued.”
MethodResultInfluentialFogari, R., Mugellini, A., Zoppi, A., Preti, P. S., Maffioli, P., Perrone, T., & Derosa, G. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.772981 · Cited by 6
“Whereas the AVOID trial [20] showed that aliskiren had additional renoprotective effects when added in hypertensive type 2 diabetic patients with nephropathy who were receiving the recommended maximal renoprotective treatment with an ARB, the more recent results of the ALTITUDE trial [52] indicated that the addition o…”
ResultRenal Disease in Diabetes Mellitus: Recent Studies and Potential Therapies
Iqbal, S. (2013) · Journal of Diabetes & Metabolism · doi:10.4172/2155-6156.s9-006 · Cited by 7
“However the ALTITUDE study to combine ARB and Aliskiren, resulted in early termination of the study to due higher risk of cerebrovascular events [143].”
BackgroundAn evaluation of the latest evidence relating to renin–angiotensin system inhibitors
Escobar, C., & Barrios, V. (2013) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2013.788149 · Cited by 6
Tran, T., & Giang, N. M. (2014) · IJC Metabolic & Endocrine · doi:10.1016/j.ijcme.2014.01.001 · Cited by 14
Pollock, C. A., Żuk, A., Anders, H., Ganji, M. R., Johnson, D. W., Kasiske, B. L., Langham, R. G., Pecoits‐Filho, R., Remuzzi, G., Rossert, J., et al. (2017) · Kidney International Supplements · doi:10.1016/j.kisu.2017.07.008 · Cited by 7
Nitta, K., Nagai, T., Mizunuma, Y., Kitada, M., Nakagawa, A., Sakurai, M., Toyoda, M., Haneda, M., Kanasaki, K., & Koya, D. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01733-6 · Cited by 6
Alaraj, M. (2020) · Veterinary World · doi:10.14202/vetworld.2020.2658-2662 · Cited by 6
Rossing, P. R. (2021) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfab243 · Cited by 8
sGC stimulation lowers elevated blood pressure in a new canine model of resistant hypertension
Vogel, J. K., Boehme, P., Homann, S., Boehm, M., Schütt, K. A., Boden, K., Balitzki, J., Hüser, J., Dinh, W., Truebel, H., et al. (2021) · Hypertension Research · doi:10.1038/s41440-021-00748-5 · Cited by 6
“Current pharmacologic treatment options for rHTN in addition to standard antihypertensive therapy include alpha blockers [12], direct renin inhibitors [13, 14], central sympatholytics, direct vasodilators [15] and mineralocorticoid receptor antagonists [16].”
BackgroundAntisense Oligonucleotide: A Potential Therapeutic Intervention for Chronic Kidney Disease
Li, Y., Tan, Y., Zhang, R., Wang, T., Na, N., Zheng, T., Veedu, R. N., & Chen, S. (2022) · Kidney and Dialysis · doi:10.3390/kidneydial2010004 · Cited by 7
“…treatments including ACEi plus ARB, renin inhibitor plus ACEi, or renin inhibitor plus ARB were evaluated; however, the results were unsatisfactory in that unacceptable side effects such as hypotension, increased hyperkalemia, and AKI were observed, leading to the termination of the trials [54,55].”
BackgroundPaneni, F., & Cosentino, F. (2015) · Springer eBooks · doi:10.1007/978-3-319-17762-5_10 · Cited by 6
Adams, J., & Mosler, C. (2022) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2022.2098118 · Cited by 6
Nakamoto, H., Fujita, T., Origasa, H., Isono, M., Kurumatani, H., Okada, K., Kanoh, H., Kiriyama, T., & Yamada, S. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-153 · Cited by 6
“Clinical benefits of combination treatments with multiple RAS inhibitors are therefore unproven, at least for diabetic nephropathy [7-10].”
BackgroundComprehensive Care for People With Diabetic Kidney Disease
Jain, K., & Mottl, A. K. (2015) · Diabetes Spectrum · doi:10.2337/diaspect.28.3.187 · Cited by 7
“Th ese trials were stopped prematurely because of safety concerns (hyperkalemia and acute kidney injury), and there was no evidence of benefi t to combination RAAS therapy with respect to primary outcomes (12,13).”
BackgroundYu, H., Zhao, X., Shan, X., Li, P., & Chen, T. (2015) · Asian Pacific Journal of Tropical Medicine · doi:10.1016/j.apjtm.2015.10.010 · Cited by 6
RetractedThe Impact of Cardiovascular Drugs on Glycemic Control: A Review
Grodzinsky, A., Arnold, S. V., Jacob, D., Draznin, B., & Kosiborod, M. (2016) · Endocrine Practice · doi:10.4158/ep161309.ra · Cited by 8
The impact of antihypertensives on kidney disease
Márquez, D. F., Ruiz‐Hurtado, G., & Ruilope, L. M. (2017) · F1000Research · doi:10.12688/f1000research.9916.1 · Cited by 7
Treatment of Hypertension in Chronic Kidney Disease
Wühl, E., & Schaefer, F. S. (2019) · Updates in hypertension and cardiovascular protection · doi:10.1007/978-3-030-18167-3_15 · Cited by 6
New Molecules for Treating Resistant Hypertension: a Clinical Perspective
Azzam, O., Kiuchi, M. G., Ho, J. K., Matthews, V. B., Lugo‐Gavidia, L. M., Nolde, J. M., Carnagarin, R., & Schlaich, M. P. (2019) · Current Hypertension Reports · doi:10.1007/s11906-019-0978-z · Cited by 6
Lizakowski, S., Tylicki, L., Rutkowski, P., Renke, M., Sulikowska, B., Heleniak, Z., Donderski, R. Ł., Bednarski, R., Przybylska, M., Manitius, J., et al. (2013) · Polskie Archiwum Medycyny Wewnętrznej · doi:10.20452/pamw.1726 · Cited by 6
Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine
Borghi, C., Morbini, M., & Cicero, A. F. G. (2015) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000240 · Cited by 7
Losing ALTITUDE? How should ASTRONAUT Launch into ATMOSPHERE
Krum, H., Massie, B. M., Abraham, W. T., Dickstein, K., Køber, L., & McMurray, J. J. V. (2013) · European Journal of Heart Failure · doi:10.1093/eurjhf/hft133 · Cited by 6
Self-citationCao, Z., Gao, X., Meng, J., Guo, X., Xu, J., Cui, J., & Zhou, X. (2023) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2023.05.008 · Cited by 5
Multifactorial chronic kidney disease
Guerra, J. M. A., & Martinez-Martinez, J.-I. (2025) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaf122 · Cited by 6
Treatment Strategies to Prevent Renal Damage in Hypertensive Children
Czarniak, P., & Zurowska, A. M. (2014) · Current Hypertension Reports · doi:10.1007/s11906-014-0423-2 · Cited by 7
Shah, S., Coakley, C., Hough, A. R., & Parra, D. (2013) · Annals of Pharmacotherapy · doi:10.1177/1060028013501142 · Cited by 5
“This FDA warning was based on preliminary results from the ALTITUDE trial, which showed an increased risk of hyperkalemia, hypotension, and renal impairment in the diabetic group taking aliskiren in addition to ACEIs or ARBs.(23,24) These patients had a baseline average BP of 137/74 mm Hg and represent a group that pe…”
ResultUpdate on ivabradine for heart failure
BORER, J. S., & Tavazzi, L. (2016) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2016.01.004 · Cited by 5
“However, trials testing the effects of a drug directly counteracting renin activity did not show clear benefits in chronic HF [4,5].”
BackgroundDPP-4 inhibition and blood pressure lowering in perspective
Nilsson, P. M., & Díez, J. (2015) · Journal of Hypertension · doi:10.1097/hjh.0000000000000814 · Cited by 5
“Other drugs blocking renin–angiotensin system have been less successful, for example, aliskiren in the aliskiren trial in type 2 diabetes using cardiovascular and renal disease endpoints (ALTITUDE) trial [22].”
MethodJiménez, D. L., Guerra, L. C., Chozas, J. M. L., & Miramontes‐González, J. P. (2017) · Medicina Clínica · doi:10.1016/j.medcli.2017.05.027 · Cited by 5
Lie, D. N. W., Chan, K. W., Tang, A. H. N., Chan, A. T. P., Chan, G. C. W., Lai, K. N., & Tang, S. C. W. (2023) · Journal of Nephrology · doi:10.1007/s40620-022-01530-7 · Cited by 5
“The aliskiren trial in type 2 diabetes using cardiorenal endpoints (ALTITUDE) study showed that the longterm effects of aliskiren increased renal complications, hyperkalemia, hypotension and non-fatal stroke in a group of diabetic nephropathy patients [13].”
BackgroundYokoyama, Y., Hanai, K., Mori, T., Yamamoto, Y., Yoshida, N., Murata, H., Shinozaki, T., & Babazono, T. (2023) · Clinical and Experimental Nephrology · doi:10.1007/s10157-023-02328-y · Cited by 5
“In the Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints (ALTITUDE) and the Veterans Affairs Nephropathy in Diabetes (VA NEPHRON-D) study, dual blockade of renin–angiotensin–aldosterone system reduced urinary albumin but not risk for kidney failure [26, 27], which might be partly explained by the present…”
BackgroundHarada, W., Maeoka, Y., Takahashi, A., Yoshida, M., Osaki, Y., Ishiuchi, N., Sasaki, K., & Masaki, T. (2024) · CEN Case Reports · doi:10.1007/s13730-024-00934-7 · Cited by 5
Uchida, H. A., Wada, J., Motoki, H., Kuwahara, K., Kario, K., Katsuya, T., Shimosawa, T., Tsujita, K., Suzuki, S., Suedomi, T., et al. (2025) · Hypertension Research · doi:10.1038/s41440-025-02259-z · Cited by 8
“Although reduction in UACR has not been consistently linked with hard outcomes in some clinical trials, such as ALTITUDE or VA NEPHRON-D [40, 41], reducing proteinuria remains clinically important.”
Tocci, G., Palano, F., Battistoni, A., Citoni, B., Musumeci, B., Ferrucci, A., Borghi, C., & Volpe, M. (2015) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2015.05.003 · Cited by 5
“Also, the results of recent randomised clinical trials have questioned the clinical benefits obtained by achieving such rigorous BP control in patients at high or very high cardiovascular risk, with or without hypertension [21,22].”
Puri, R., Nissen, S. E., Menon, V., Shao, M., Hsu, A., Bakris, G. L., Kastelein, J. J. P., Williams, B., Armbrecht, J., Brunel, P., et al. (2015) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2015.10.019 · Cited by 5
Self-citationComplete inhibition of the renin–angiotensin–aldosterone system; where do we stand?
Chen, S. S., Seliger, S. L., & Fried, L. F. (2014) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000043 · Cited by 7
“The latter negative finding is notable in light of the significant reduction in albuminuria in the aliskiren group [49].”
BackgroundKing, M. A., & Pryce, R. (2013) · International Journal of Clinical Pharmacy · doi:10.1007/s11096-013-9893-6 · Cited by 7
“[31] Type 2 diabetes Initial dose alskiren 150 mg (increased to 300 mg at 4 weeks if no safety concerns) or placebo, once daily; median follow- up 32.”
BackgroundBlood Pressure Control in Diabetic Nephropathy
Tkachenko, O. (2014) · Journal of Nephrology & Therapeutics · doi:10.4172/2161-0959.1000148 · Cited by 5
“After these promising results premature termination of the ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiorenal Endpoints) study was disappointing [68].”
BackgroundTratamiento de la poliquistosis renal autosómica dominante
Torrá, R. (2013) · Medicina Clínica · doi:10.1016/j.medcli.2013.09.018 · Cited by 5
Prevalent Diabetes Mellitus: Mortality and Management in Norwegian Heart Failure Outpatients
Stubnova, V., Os, I., Grundtvig, M., & Waldum-Grevbo, B. E. (2016) · Cardiology · doi:10.1159/000444658 · Cited by 5
Hong, Z., Wu, T., Zhou, S., Huang, B., Wang, J., Jin, D., & Geng, D.-F. (2018) · Journal of Human Hypertension · doi:10.1038/s41371-017-0026-x · Cited by 5
“In this systematic review, the first co-primary outcomes originated from the composite CVD events, as defined by the study.”
BackgroundInfluentialEfficacy of aliskiren supplementation for heart failure
Luo, Y., & Chen, Q. (2018) · Herz · doi:10.1007/s00059-018-4679-1 · Cited by 5
Yang, X., Xiao, X., Wang, H., Li, Y., Wang, L., Li, G., & Deng, S. (2018) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2018/3450141 · Cited by 5
“For example, recently, a multinational prospective randomized controlled trial involving 8561 patients with type 2 diabetesmellitus and chronic kidney disease was prematurely terminated because of the severe adverse events of aliskiren, including increased risk of acute kidney injury, hyperkalemia, hypotension, and st…”
BackgroundFuture and Novel Compounds in the Treatment of Diabetic Nephropathy
Idzerda, N. M. A., Pena, M. J., de Zeeuw, D., & Heerspink, H. J. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-93521-8_29 · Cited by 5
Emerging paradigms of treating diabetic nephropathy
Chang, Y., Moradi, H., & Kalantar‐Zadeh, K. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30304-8 · Cited by 5
RETROSPECTIVE STUDY ON ANGIOTENSIN-CONVERTING-ENZYME INHIBITORS TREATMENT
Maghiar, F. (2020) · FARMACIA · doi:10.31925/farmacia.2020.1.13 · Cited by 5
“(ARBs), ACE-I or aliskiren is not recommended in any patient [5, 16, 19].”
BackgroundLiuzzo, G., & Volpe, M. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad593 · Cited by 5
Renin Angiotensin Aldosterone System Blockers
Shibata, S., & Fujita, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-88369-6.00022-0 · Cited by 7
Diabetes and Chronic Kidney Disease
Kara, M. T., Levi, M., & Choudhury, D. (2014) · Springer eBooks · doi:10.1007/978-3-642-54637-2_4 · Cited by 5
“Similarly combination use of a direct renin inhibitor (aliskiren) with either an ACEI or ARB did not preserve kidney function and was associated with increased events of hypotension and hyperkalemia [ 16 ].”
BackgroundCapítulo 5 - Decisão e Metas Terapêuticas
Malachias, M. V. B., Souza, W., Plavnik, F. L., Rodrigues, C., Brandão, A., Neves, M. F., Bortolotto, L. A., Franco, R., Figueiredo, C., Jardim, P., et al. (2016) · Arquivos Brasileiros de Cardiologia · doi:10.5935/abc.20160155 · Cited by 10
Dörks, M., Herget‐Rosenthal, S., Hoffmann, F., & Jobski, K. (2018) · Clinical Interventions in Aging · doi:10.2147/cia.s159715 · Cited by 5
Treating diabetic complications; from large randomized clinical trials to precision medicine
Heerspink, H. J. L., & de Zeeuw, D. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13418 · Cited by 5
Vasudevan, A., Choi, J. W., Feghali, G. A., Kluger, A. Y., Lander, S. R., Tecson, K. M., Sathyamoorthy, M., SCHUSSLER, J. M., Stoler, R., Vallabhan, R. C., et al. (2019) · Scandinavian Cardiovascular Journal · doi:10.1080/14017431.2019.1645349 · Cited by 6
“For example, The Aliskiren Trial in Type 2 Diabetes Using Cardio renal Endpoints (ALTITUDE) study employed a primary cardio renal composite outcome considering clinical events pertaining to cardiac and/or renal disease [15].”
MethodThe Concept of Early Vascular Ageing – An Update in 2015
Nilsson, P. M. (2015) · EMJ Diabetes · doi:10.33590/emjdiabet/10312465 · Cited by 5
Are Triplicate Urine Samples Necessary to Assess Albuminuria?
Deeb, A., Zaoui, P., Penven, S. L., Tartry, D., Lantelme, P., Ducher, M., & Fauvel, J. (2013) · Nephron Clinical Practice · doi:10.1159/000350429 · Cited by 5
Catalá-López, F., Saint-Gerons, D. M., Honrubia, C. D. L. F., & Martín-Serrano, G. (2014) · Revista Española de Salud Pública · doi:10.4321/s1135-57272014000100004 · Cited by 5
Aliskiren reduces albuminuria after kidney transplantation
Tylicki, L., Dębska-Ślizień, A. M., Lizakowski, S., Przybylska, M., Heleniak, Z., Renke, M., Chamienia, A. L., Biedunkiewicz, B., Rutkowski, P., Małgorzewicz, S., et al. (2017) · Acta Biochimica Polonica · doi:10.18388/abp.2016_1297 · Cited by 5
“Although the functional and morphological findings in this pathology are well characterised, no effective therapy has been developed so far to prevent, limit, or reverse graft lesions (Paul, 1999).”
BackgroundMa, Y.-P., Yang, Y., Jiang, S., Liu, L., Zhang, Z., Wang, Y., Zou, G., & Li, W. (2020) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320320919607 · Cited by 6
Heart Failure in Diabetes Mellitus: An Updated Review
Sohrabi, C., Saberwal, B., Lim, W. Y., Tousoulis, D., Ahsan, S., & Παπαγεωργίου, Ν. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666201118091659 · Cited by 5
Risk Stratification of Resistant Hypertension in Chronic Kidney Disease
Weinrauch, L. A., Desai, A. S., Skali, H., & D’Elia, J. A. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.03.048 · Cited by 5
“, sodium restriction, combination renin-angiotensinaldosterone system blockade, aldosterone antagonists) are ineffective or associated with higher risk in populations with CKD (9,10).”
BackgroundSelf-citationResistant Hypertension: A Real Entity or a Phantom Diagnosis?
Thomopoulos, C., Skalis, G., & Makris, T. K. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12565 · Cited by 5
Khattab, M. A., Khalil, S. H. A., Bassyouni, A., Fawzy, F., Elgayar, A. H., Elebrashy, I., Elhadidy, K. E., Abdallah, K., El-Hefnawy, M. H., Halawa, M. R., et al. (2025) · BMC Family Practice · doi:10.1186/s12875-025-03091-7 · Cited by 5
“A combination of an ACE-I with an ARB is not recommended due to a lack of evidence for additional cardiovascular benefits and an increased risk of adverse events, including hyperkalemia, hypotension, and acute kidney injury [125–128].”
Hagiwara, S., Jha, J. C., & Cooper, M. E. (2013) · Diabetology International · doi:10.1007/s13340-013-0148-5 · Cited by 4
“Furthermore, this combination resulted in an increased number of adverse events such as hyperkalemia or hypotension [51], and therefore there is now reduced enthusiasm for this dual RAS blockade approach.”
BackgroundRistić, P., Srejovic, I. M., Nikolic, T. R., Milosavljevic, I. M., Ristić, D., Zivkovic, V. I., & Jakovljevic, V. L. (2016) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-016-2890-z · Cited by 6
Wang, S., Djama, N. M., Lai, Y., Li, H., Liao, W., Liao, Y., & Bin, J. (2019) · Journal of Clinical Hypertension · doi:10.1111/jch.13471 · Cited by 4
Álvarez-Aliaga, A., Guerra, A. F., Quesada, A. S., Llano-Sosa, D. D., Saumell, J. B., & Santiesteban, Y. A. L. (2020) · Medwave · doi:10.5867/medwave.2020.03.7873 · Cited by 6
Xia, Y., Jiang, H., Chen, J., Xu, F., Zhang, G., & Zhang, D. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.121540 · Cited by 4
The changing landscape of drug clinical trials on cardiometabolic diseases in China, 2009–2021
Li, C., Hao, J., Zheng, Y., Wang, C., Yang, J., Wang, W., Zhang, K., Shao, C., Wen, H., Wang, J., et al. (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01043-8 · Cited by 4
“And the angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) combination failed because of the increased risks of hyperkalemia, and renal insufficiency [41, 42] From the perspective of drug mechanism, the top 20 drug trials were dominated by antihypertensive drugs, hypoglycemic dru…”
BackgroundA brief approach to hypertension in type 2 diabetes mellitus
Güneş, Y. (2025) · Exploration of Endocrine and Metabolic Diseases · doi:10.37349/eemd.2025.101422 · Cited by 10
Meta-analyses can misdirect decisions on treatment
Ruggenenti, P. L., & Remuzzi, G. (2013) · Nature Reviews Nephrology · doi:10.1038/nrneph.2013.82 · Cited by 4
Dual RAAS blockade has dual effects on outcome
Heerspink, H. J. L., & de Zeeuw, D. (2013) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.65 · Cited by 4
Serum Potassium in Dual Renin-Angiotensin-Aldosterone System Blockade
Seliger, S. L., & Fried, L. F. (2014) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.12411213 · Cited by 4
Habib, G. B., & Basra, S. S. (2014) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248414529620 · Cited by 4
“Aliskiren is a direct RI and is the first RI to be approved by the FDA for the treatment of hypertension in April 2007, based on its BP-lowering efficacy in 6 placebo-controlled, 8-week clinical trials involving >2000 patients with hypertension and an acceptable safety profile in >6460 patients(41) However, a postmark…”
BackgroundKintscher, U., & Mahfoud, F. (2015) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0041-102097 · Cited by 4
Pathophysiology of Chronic Kidney Disease
Whittier, W. L., & Lewis, E. J. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4617-0.00052-2 · Cited by 4
Renin Angiotensin Aldosterone System Blockers
Shibata, S., & Fujita, T. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-42973-3.00024-x · Cited by 7
Saiz-Satjes, M., & Martínez-Martín, F. J. (2018) · Drugs in Context · doi:10.7573/dic.212509 · Cited by 7
Anti-Diabetic Agents and Heart Failure ― Response to the CARMELINA Study ―
Sano, M. (2018) · Circulation Reports · doi:10.1253/circrep.cr-18-0011 · Cited by 4
Alexandrou, M. E., Theodorakopoulou, M. P., Kanbay, M., & Sarafidis, P. A. (2022) · Journal of Human Hypertension · doi:10.1038/s41371-021-00641-1 · Cited by 6
“However, in all renal outcome trials and subsequent meta-analyses single RAS-blockade was not associated with significant reductions in cardiovascular outcomes, whereas the combination of these two classes in the ALTITUDE and NEPHROND trials was associated with increase in the risk of serious adverse events and was ab…”
BackgroundResultInfluentialThe Renin–Angiotensin–Aldosterone System and the Kidney
Ko, B. S., & Bakris, G. L. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-803247-3.00002-7 · Cited by 5
Cao, Z., Gao, X., Meng, J., Guo, X., Xu, J., Cui, J., & Zhou, X. (2023) · Nefrología · doi:10.1016/j.nefro.2023.02.009 · Cited by 5
Understanding and Treatment Strategies of Hypertension and Hyperkalemia in Chronic Kidney Disease
Jo, S. M. (2023) · Electrolytes & Blood Pressure · doi:10.5049/ebp.2023.21.1.24 · Cited by 5
Cardiovascular Toxicity of Cardiovascular Drugs
Meenakshisundaram, R., Cannie, D. E., Shankar, P. R., Zadeh, H. Z., Bajracharya, O., & Thirumalaikolundusubramanian, P. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416595-3.00008-6 · Cited by 5
Dushay, J. R., Tecilazich, F., Kafanas, A., Magargee, M. L., Auster, M. E., Gnardellis, C., Dinh, T., & Veves, A. (2013) · Journal of the Renin-Angiotensin-Aldosterone System · doi:10.1177/1470320313489060 · Cited by 4
Hypertension and Chronic Kidney Disease
Riggen, S., & Agarwal, R. (2014) · Springer eBooks · doi:10.1007/978-3-642-54637-2_5 · Cited by 4
New strategies to tackle diabetic kidney disease
Batu, D., & Cooper, M. E. (2016) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000234 · Cited by 5
“Furthermore, combination therapies using ACEIs and ARBs or ARBs and renin inhibitors have demonstrated disappointing results in clinical trials with serious side-effects such as hyperkalemia and occasional exacerbation of renal impairment [29].”
BackgroundDiabetes and the Kidney: Sweet Dreams
Novak, J. E., & Yee, J. (2018) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2018.01.001 · Cited by 4
ACE-I und ARB bei chronischen Nierenerkrankungen: Was muss ich berücksichtigen?
Zeier, M. G. (2018) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/a-0549-9662 · Cited by 4
“In einer Metaanalyse an 105 872 Teilnehmern konnte eine lineare Assoziation von eGFR und Albuminurie mit der Herz-Kreislauf-Sterblichkeit eindrucksvoll belegt werden [29].”
BackgroundInfluentialTocci, G., Citoni, B., Presta, V., Leoncini, G., Viazzi, F. C., Bonino, B., Volpe, M., & Pontremoli, R. (2019) · Internal and Emergency Medicine · doi:10.1007/s11739-019-02257-3 · Cited by 4
Slowing Progression of Chronic Kidney Disease
Drawz, P. E., Hostetter, T. H., & Rosenberg, M. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-411602-3.00049-4 · Cited by 6
Munro, M. J., Peng, L., Wickremesekera, S. K., & Tan, S. T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0256280 · Cited by 4
“Renin can be directly antagonized using aliskiren; however, administration of aliskiren is generally avoided in favor of drugs with fewer side effects and higher bioavailability [62].”
BackgroundWeng, S., Shu, K., Wu, M.-J., Wen, M., Hsieh, S.-L. E., Chen, N., & Tarng, D. (2015) · Scientific Reports · doi:10.1038/srep12769 · Cited by 4
Ozeki, A. N., Amiya, E., Watanabe, M., Hosoya, Y., Takata, M., Watanabe, A., Kawarasaki, S., Nakao, T., Watanabe, S., Omori, K., et al. (2014) · Journal of Clinical Hypertension · doi:10.1111/jch.12366 · Cited by 4
“This result corresponded with the findings of the Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints (ALTITUDE) trial, where patients taking aliskiren with high baseline potassium values demonstrated an increased hazard ratio of cardiovascular events.(30) It is speculated that hyperkal…”
ResultClark, A. L. (2013) · Heart · doi:10.1136/heartjnl-2013-304761 · Cited by 4
Combination therapy in chronic kidney disease?
Juncos, L. I., & Caputo, J. (2015) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/1753944715579628 · Cited by 5
“2008], the Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE) [Parving et al.”
InfluentialWasser, W. G., Gil, A., & Skorecki, K. L. (2015) · Rambam Maimonides Medical Journal · doi:10.5041/rmmj.10214 · Cited by 5
Metadata
- Authors
- Parving, H.-H., Brenner, B. M., McMurray, J. J. V., de Zeeuw, D., Haffner, S. M., Solomon, S. D., Chaturvedi, N., Persson, F., Desai, A. S., Nicolaides, M., Richard, A., Xiang, Z., Brunel, P., & Pfeffer, M. A.
- Affiliations
- University of Copenhagen (DK)
- Brigham and Women's Hospital (US)
- The University of Texas at San Antonio Health Science Center (US)
- Imperial College London (GB)
- Steno Diabetes Centers (DK)
- Novartis (Switzerland) (CH)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-12-06
- Volume
- 367
- Issue
- 23
- Pages
- 2204-2213
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2138862624
- Cited by
- 1,319
- References
- 40
- Citations by year
- 2026: 30 · 2025: 41 · 2024: 52 · 2023: 68 · 2022: 61 · 2021: 75 · 2020: 73 · 2019: 96 · 2018: 93 · 2017: 124 · 2016: 117 · 2015: 151 · 2014: 166 · 2013: 159 · 2012: 11
- FWCI
- 100.24
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- other-oa
- Locations
- New England Journal of Medicine (publishedVersion, other-oa)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, other-oa)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion, other-oa)
- Research Bank (Australian Catholic University) (submittedVersion)
- Institutional Research Information System (University of Udine) (submittedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Cineca Institutional Research Information System (Tor Vergata University) (submittedVersion)
- Bern Open Repository and Information System (University of Bern) (submittedVersion, other-oa)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Florence Research (University of Florence) (submittedVersion)
- IRIS (submittedVersion)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- UnissResearch (Università degli Studi di Sassari) (submittedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (submittedVersion)
- SERVAL (Université de Lausanne) (submittedVersion)
- Use Siena air (University of Siena) (submittedVersion, other-oa)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion)
- Open Access CRIS of the University of Bern
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Renin-Angiotensin System Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- aliskiren, type 2 diabetes, chronic kidney disease, renin-angiotensin system blockade, ACE inhibitors, angiotensin receptor blockers, cardiovascular events, end-stage renal disease, hyperkalemia, hypotension, albumin-creatinine ratio, blood pressure reduction, cardiorenal outcomes
- MeSH terms
- Renin Inhibitors, Aged, Amides, Angiotensin-Converting Enzyme Inhibitors, Antihypertensive Agents, Cardiovascular Diseases, Diabetes Mellitus, Type 2, Double-Blind Method, Drug Therapy, Combination, Female, Follow-Up Studies, Fumarates, Humans, Hyperkalemia, Hypokalemia, Kidney Diseases, Male, Middle Aged, Patient Dropouts, Treatment Failure, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.